Skip to main navigation menu Skip to main content Skip to site footer
FrancoAngeli Journals

Saggi, Studi e Ricerche

No. 69 (2025)

Patient satisfaction and economic feasibility of weekly and monthly subcutaneous buprenorphine for opioid use disorder: A qualitative and semi-quantitative analysis

DOI
https://doi.org/10.3280/mis69-2025oa19140
Submitted
gennaio 10, 2025
Published
2025-05-20

Abstract

Opioid Use Disorder (OUD) is a complex chronic condition characterized by physical and psychological dependence, with high rates of morbidity and mortality. Although oral Opioid Agonist Therapy (OAT) is currently the first-line treatment, adherence remains a significant issue. This study explores patients' acceptance and expectations toward a new long-acting subcutaneous weekly/monthly buprenorphine formulation. A survey was conducted on 100 OUD patients at the Integrated Multidisciplinary Service (I.M.S.) Gli Acrobati, investigating their preferences and economic willingness to support this new therapeutic option. The results show a strong interest in the long-acting formulation, with 57% of patients expressing maximum satisfaction. Participants identified the main benefits as reduced frequency of administration and greater stability in managing dependence. 93% of respondents indicated they were willing to cover costs ranging between €1 and €5 per day, with a variable duration from 1 to 12 months. This survey provides an initial qualitative assessment of patient preferences and their willingness to contribute to the costs of the new long-acting therapy, highlighting the potential for improving OUD treatment and the need for further studies on the long-term clinical and economic impact.

References

  1. Dydyk A.M., Jain N.K., Gupta M. (2024 Jan 17). Opioid Use Disorder. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
  2. Christie M.J. (2008). Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol., May 29, 154(2): 384-96.
  3. American Society of Addiction Medicine (ASAM). Definition of addiction. -- www.asam.org/docs/default-source/quality-science/asam’s-2019-definition-of-addiction-(1).pdf?sfvrsn=b8b64fc2_2 (Ultimo accesso: 27/8/2024).
  4. Alho H., Dematteis M., Lembo D., Maremmani I., Roncero C., Somaini L. (2020). Opioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concern. International Journal of Drug Policy, Feb, 76, 102616.
  5. Chang H.Y., Kharrazi H., Bodycombe D., Weiner J.P., Alexander G.C. (2018). Healthcare costs and utilization associated with highrisk prescription opioid use: a retrospective cohort study. BMC Med., May 16, 16(1): 69.
  6. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization; 2009. 3, Background. -- www.ncbi.nlm.nih.gov/books/NBK143178/ (Ultimo accesso: 2778/2024).
  7. NICE Guidance Overview. Drug misuse in over 16s: opioid detoxification. -- www.nice.org.uk/guidance/cg52 (Ultimo accesso: 27/8/2024).
  8. The ASAM National Practice Guideline 2020 Focused Update. -- www.iss.it/documents/20126/0/Linee-Guisa-ASAM_2020.pdf/b4a81d64-374c-fb54-302d-e77460bc3ab2?t=1588167692291 (Ultimo accesso: 27/8/2024).
  9. European Monitoring Centre for Drugs and Drug Addiction. Balancing Access to Opioid Substitution Treatment with Preventing the Diversion of Opioid Substitution Medications in Europe: Challenges and Implications. 2021. -- www.emcdda.europa.eu/publications/technical-reports/opioid-substitutiontreatment-ost-in-europe-availability-and-diversion_en (Ultimo accesso: 27/8/2024).
  10. Dematteis M., Auriacombe M., D’Agnone O., Somaini L., Szerman N., Littlewood R. et al. (2017). Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmacother., Dec 12, 18(18): 1987-99.
  11. Mégarbane B., Hreiche R., Pirnay S., Marie N., Baud F.J. (2006). Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences. Toxicol Rev., 25(2): 79-85.
  12. Bonhomme J., Shim R.S., Gooden R., Tysu D., Rust G. (2012). Opioid Addiction and Abuse in Primary Care Practice: A Comparison of Methadone and Buprenorphine as Treatment Options. J Natl Med Assoc., Jul, 104(7-8): 342-50.
  13. Stöver H. (2012). Outcomes of opioid-dependence treatment across Europe: Identifying opportunities for improvement. Heroin Addict Relat Clin Probl., Dec 1, 14: 39-50.
  14. Dale-Perera A., Goulao J., Stover H. (2012). Quality of care provided to patients receiving opioid maintenance treatment in Europe: results from the EQUATOR analysis. Heroin Addict Relat Clin Probl., 14(4): 23-38.
  15. Advisory Council on the Misuse of Drugs. How can opioid substitution therapy (and drug treatment and recovery systems) be optimised to maximise recovery outcomes for service users? (2015). -- https://assets.publishing.service.gov.uk/media/5a7f4d88e5274a2e87db5087/ACMD_RC_OPTIMISING_OST_REPORT_231015.pdf (Ultimo accesso: 27/8/2024).
  16. Rolland B., Trojak B., Nourredine M., Bachellier J., Chappuy M., Bendimerad P. et al. (2021). Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone. Drug Alcohol Depend., Mar 1, 220, 108492.
  17. Frost M., Bailey G.L., Lintzeris N., Strang J., Dunlop A., Nunes E.V. et al. (2019). Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Addiction, Aug, 114(8): 1416-26.
  18. Barnett A., Pienaar K., Lubman D.I., Arunogiri S., Phan V., Hayes V. et al. (2024). The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients’ experiences. Int J Drug Policy, May, 127, 104399.
  19. Little S., White B., Moensted M., Butler K., Howard M., Roberts J. et al. (2023). Health and correctional staff acceptability of depot buprenorphine in NSW prisons. Int J Drug Policy, Apr, 114, 103978.
  20. Allegato alla Determina AIFA Numero Rep. n. 102/2021 del 26/07/2021. -- www.aifa.gov.it /documents/20142/1546128/DETERMINA_102-2021_BUDIVAL.pdf (Ultimo accesso: 27/8/2024).
  21. Riassunto delle Caratteristiche del Prodotto (RCP). European Medicine Agency (EMA). -- https://ec.europa.eu/health/documents/community-register/2018/20181120142634/anx_142634_it.pdf (Ultimo accesso: 27/8/2024).
  22. Lofwall M.R., Walsh S.L., Nunes E. V., Bailey G.L., Sigmon S.C., Kampman K.M. et al. (2018). Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder. JAMA Intern Med., Jun 1, 178(6): 764.
  23. European Commission. Buvidal, INN-buprenorphine. Allegato I, riassunto delle caratteristiche del prodotto. -- https://ec.europa.eu/health/documents/community-register/2018/20181120142634/anx_142634_it.pdf (Ultimo accesso: 11/9/2024).
  24. Mannaioni G., Lugoboni F. (2023). Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system. Drugs Context., 12.
  25. Dasgupta N., Bailey E.J., Cicero T., Inciardi J., Parrino M., Rosenblum A. et al. (2010). Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med., Jul, 11(7): 1078-91.
  26. ANSM. Suivi national addictovigilance de la methadone – Rapport d’Exper tise Novembre 2019. Centre d’Addictovigilance PACA Corse; 2020. -- https://ansm.sante.fr/uploads/2020/10/13/20201013-rappor t-methadone-ceipnovembre-2019.pdf.
  27. Lapeyre-Mestre M., Boucher A., Daveluy A., Gibaja V., Jouanjus E., Mallaret M. et al. (2020). Addictovigilance contribution during COVID-19 epidemic and lockdown in France. Therapie., 75(4): 343-54.
  28. Boucherie Q., Frauger E., Thirion X., Mallaret M., Micallef J. (2015). New methadone formulation in France: results from 5 years of utilization. Therapie, 70(2): 223-34.
  29. Gilman M., Li L., Hudson K., Lumley T., Myers G., Corte C. et al. (2018). Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine. Patient Prefer Adherence, Oct, 12, 2123-9.
  30. Neale J., Tompkins C.N.E., Strang J. (2019). Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations. Harm Reduct J., Dec 3, 16(1): 25.
  31. Férey M., Dubernet J., Auriacombe M. (2023). Cost estimation analysis for supervised dispensing of sublingual buprenorphine treatment and long-acting buprenorphine at Charles-Perrens hospital. Le Courrier des Addictions, XXV(4), octobre-novembre-décembre. -- www.edimark.fr/revues/le-courrier-des-addictions/vol-xxv-n-4/estimation-des-couts-theoriques-dune-delivrance-superviseeduntraitement-par-buprenorphine-sublinguale-etdebuprenorphinedaction-prolongee-encsapa-aucentre-hospitalier-charles-perrens.
  32. Terrail N., Meroueh F. (2023). Analyse d’impact budgétaire de l’utilisation de la buprénorphine à libération prolongée en milieu carceral Bilan après 2 ans de pratique au centre pénitentiaire de Villeneuve-lès-Maguelone. Le Courrier des Addictions, XXV(4), octobre-novembre-décembre. -- www.edimark.fr/revues/lecourrier-des-addictions/vol-xxv-n-4/analyse-dimpact-budgetairedelutilisation-delabuprenorphine-a-liberation-prolongeeenmilieucarceral.
  33. Wright N., Hard J., Fearns C., Gilman M., Littlewood R., Clegg R. et al. (2020). OUD Care Service Improvement with Prolongedrelease Buprenorphine in Prisons: Cost Estimation Analysis. Clinico econ Outcomes Res., 12: 499-504.
  34. Ling R., White B., Roberts J., Cretikos M., Howard M. V., Haber P.S. et al. (2022). Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model. BMC Health Serv Res., Nov 8, 22(1), 1326.
  35. Stöver H., Keppler K. (2023). Opioid Substitution Treatment in Prisons: Comparison of Cost of Buprenorphine Depot with other Medications – a Health-Economic Calculation. Gesundheitswesen, Jun, 85(6): 573-7.

Metrics

Metrics Loading ...